Want to see TSE:INNO full AI Analyst Report?
Top Page
InnoCan Pharma
(INNO)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$2.00
▼(-8.68% Downside)
Action:Reiterated
Date:09/15/26
The score is driven primarily by weak financial performance: the company is still unprofitable, revenue is declining, and cash flow has reverted to burn, which raises execution and funding risk despite strong gross margins and only moderate leverage. Technicals add further pressure with a clear downtrend (below key moving averages and negative MACD). Valuation is constrained by a negative P/E and no provided dividend yield to offset the lack of profitability.
Positive Factors
Strong Gross Margins
Gross margins near 90% indicate favorable product economics and provide substantial contribution from each unit of revenue. If maintained, this gives InnoCan room to fund research, commercialization, and operating needs while pursuing growth in cannabinoid products and pharmaceutical candidates.
Negative Factors
Unprofitable With Declining Revenue
Persistent losses combined with declining revenue indicate that the current business has not yet achieved durable operating scale. This weakens internal funding capacity and makes successful execution of product sales and pharmaceutical development more important to improving earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margins
Gross margins near 90% indicate favorable product economics and provide substantial contribution from each unit of revenue. If maintained, this gives InnoCan room to fund research, commercialization, and operating needs while pursuing growth in cannabinoid products and pharmaceutical candidates.
Read all positive factors
InnoCan Pharma (INNO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$9.90M
Dividend YieldN/A
Average Volume (3M)1.86K
Price to Earnings (P/E)―
Beta (1Y)-0.76
Revenue Growth-19.20%
EPS Growth42.54%
CountryCA
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.21
Shares Outstanding4,498,772
10 Day Avg. Volume721
30 Day Avg. Volume1,860
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
InnoCan Pharma Business Overview & Revenue Model
Company Description
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Pol...
How the Company Makes Money
InnoCan Pharma’s revenue model is based on (1) sales of cannabinoid-based products and (2) longer-term monetization of its pharmaceutical development pipeline. Product revenue is generated from selling formulated products (where available) through...
InnoCan Pharma Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.45M | 26.61M | 29.44M | 13.66M | 2.56M | 196.00K |
| Gross Profit | 21.22M | 23.93M | 26.19M | 11.98M | 2.11M | 121.00K |
| EBITDA | -1.09M | 130.00K | 961.00K | -3.77M | -3.85M | -10.04M |
| Net Income | -942.30K | -1.12M | -1.83M | -4.70M | -3.89M | -10.06M |
Balance Sheet | ||||||
| Total Assets | 10.35M | 10.52M | 9.26M | 6.94M | 6.98M | 12.57M |
| Cash, Cash Equivalents and Short-Term Investments | 6.44M | 6.69M | 5.01M | 3.88M | 4.95M | 11.05M |
| Total Debt | 1.66M | 930.00K | 10.00K | 33.00K | 34.00K | 1.00K |
| Total Liabilities | 2.95M | 2.29M | 2.24M | 2.55M | 751.00K | 3.56M |
| Stockholders Equity | 4.80M | 5.60M | 5.17M | 4.10M | 6.39M | 9.05M |
Cash Flow | ||||||
| Free Cash Flow | -1.54M | 479.00K | -1.59M | -3.95M | -6.09M | -6.67M |
| Operating Cash Flow | -1.52M | 495.00K | -1.58M | -3.90M | -6.07M | -6.63M |
| Investing Cash Flow | -19.55K | -15.00K | 54.00K | -84.00K | -31.00K | -48.00K |
| Financing Cash Flow | 627.54K | 1.15M | 2.70M | 2.92M | 125.00K | 15.30M |
InnoCan Pharma Technical Analysis
Negative
2.19
Price Trends
2.43
Negative
3.12
Negative
5.21
Negative
Market Momentum
-0.06
Negative
44.41
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Negative. The current price of 2.19 is below the 20-day moving average (MA) of 2.26, below the 50-day MA of 2.43, and below the 200-day MA of 5.21, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.41 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:INNO.
InnoCan Pharma Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
57 Neutral | C$29.90M | -5.60 | -13.79% | ― | -6.74% | 43.54% | |
46 Neutral | C$29.42M | -5.76 | -403.29% | ― | ― | -49.66% | |
44 Neutral | C$9.90M | -6.61 | -19.37% | ― | -19.20% | 42.54% | |
42 Neutral | C$58.28M | -0.76 | -2099.75% | ― | -100.00% | 94.43% | |
41 Neutral | C$14.11M | -3.55 | -108.44% | ― | -0.23% | -142.54% |
* Consumer Defensive Sector Average
TSE:INNO
InnoCan Pharma
1.95
-17.55
-90.00%
TSE:ATLE
Willow Biosciences Inc
0.13
-0.05
-29.73%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-13.33%
TSE:VM
Voyageur Pharmaceuticals
0.13
-0.02
-16.67%
TSE:AVCN
Avicanna
0.12
-0.16
-58.18%
InnoCan Pharma Corporate Events
Business Operations and Strategy
Innocan’s VALITIC Brand Gains BuzzFeed Boost in Push Beyond Amazon
Positive
Oct 1, 2026
Innocan Pharma’s wellness subsidiary B.I. Sky Global has gained fresh visibility for its VALITIC beauty line after the brand was highlighted by BuzzFeed for delivering “magical results” on dark spots, acne scars and uneven skin t...
Business Operations and Strategy
Innocan’s VALITIC Skincare Brand Boosts U.S. Retail Profile at Shoptalk Fall 2026
Positive
Sep 29, 2026
Innocan Pharma’s consumer wellness subsidiary B.I. Sky Global is deepening its U.S. market push as its flagship VALITIC skincare brand takes part in Shoptalk Fall 2026, a major retail industry event in Nashville connecting retailers, consume...
Business Operations and StrategyPrivate Placements and Financing
Innocan Pharma Raises C$462,477 in First Tranche of Unit Offering
Positive
Sep 23, 2026
Innocan Pharma has closed the first tranche of a private placement, issuing 247,314 units at C$1.87 each for gross proceeds of C$462,477, with each unit consisting of one common share and one warrant exercisable at C$2.50 for three years. The fina...
Business Operations and StrategyFinancial Disclosures
Innocan Pharma Q2 Revenue Falls but High Margins and Amazon Leadership Support Expansion Push
Negative
Aug 31, 2026
Innocan Pharma reported second-quarter fiscal 2026 revenue of US$5.25 million, down 25% year over year, with gross profit of US$4.77 million and a gross margin of 90.8%. The period shifted to an operating loss of US$0.51 million, despite maintaini...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.